1Kahn SE,Haffner SM,Heise MA,et al.Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy[].New England Journal of Medicine The.2006
2Li Y,Xu W,Liao Z,et al.Induction of long-term glycemic con-trol in newly diagnosed type2diabetic patients is associated with improvement of beta-cell function[].Diabetes Care.2004
3UK Prospective Diabetes Study Group.UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease[].Diabetes.1995
4D.C. Klonoff,J.B. Buse,L.L. Nielsen.Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[].Current Medical Research and Opinion.2008
5Rossi MC,Nicolucci A.Liraglutide in type 2 diabetes:from pharmacological development to clinical practice[].Acta Biomed.2009
6Kendall DM,Cuddihy RM,Bergensta RM.Clinical application of incretin -based therapy:therapeutic potential,patient selection and clinical use[].Eur Intern Med.2009
同被引文献11
1国家食品药品监督管理局.中药新药临床研究指导原则[S].2002.
2乌兰等.蒙医病证诊断疗效标准[M].北京:民族出版社,2007:38-39.
3乌云其木格,等.蒙古学百科全书医学[M].呼和浩特:内蒙古人民出版社,2012.
4Kahn SE,Haffner SM,Heise MA,et al.ADOPT Study Group.Glycemic durabitity of rusiglitazone,metformin,orglyburide monotherapu[J].N Eng J Med,2006,355(23):2427-2443.
